Does Wellbutrin cause gynaecomastia? This is a clinically important question for any male patient taking bupropion — known in the UK as Zyban, licensed solely for smoking cessation. Gynaecomastia, the benign enlargement of glandular breast tissue in males, can have many causes, including medicines that disrupt the balance between oestrogen and androgen activity. Because bupropion works as a norepinephrine and dopamine reuptake inhibitor rather than a dopamine blocker, its hormonal profile differs markedly from medicines more commonly linked to breast tissue changes. This article explores the evidence, MHRA guidance, and when to seek medical advice.

What Is Wellbutrin and How Does It Work?

Wellbutrin (bupropion) is an NDRI licensed in the UK as Zyban for smoking cessation only. It enhances dopamine and norepinephrine activity, making prolactin-mediated gynaecomastia unlikely, though hormonal breast changes involve multiple mechanisms.

Wellbutrin is a brand name for bupropion hydrochloride that is widely recognised in the United States. In the UK, bupropion is licensed solely for smoking cessation and is marketed under the brand name Zyban. It is not licensed as an antidepressant in the UK; any use for depression would be off-label and outside standard NHS prescribing practice as set out in the British National Formulary (BNF) and the electronic Medicines Compendium (emc) Summary of Product Characteristics (SmPC) for Zyban.

Bupropion belongs to the aminoketone class and works as a norepinephrine and dopamine reuptake inhibitor (NDRI). By blocking the reuptake transporters for both norepinephrine and dopamine, it increases the availability of these neurotransmitters in the synaptic cleft. Unlike many other antidepressants, bupropion has minimal effect on serotonin pathways and does not significantly interact with histamine or muscarinic receptors, giving it a notably different side-effect profile compared to selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs). It is also a potent inhibitor of the CYP2D6 enzyme, which is clinically relevant when considering drug interactions.

One pharmacologically relevant aspect of bupropion is its relatively low propensity to elevate prolactin levels. Many medicines — particularly those with dopamine-blocking activity — can raise prolactin, which may contribute to gynaecomastia in some cases. Because bupropion enhances dopaminergic activity rather than suppressing it, it is generally considered unlikely to cause prolactin-mediated hormonal side effects. However, it is important to note that most cases of gynaecomastia relate primarily to an imbalance between oestrogen and androgen activity in breast tissue, rather than to hyperprolactinaemia alone; raised prolactin is one contributing factor among several. This pharmacological distinction is relevant when evaluating whether bupropion could be responsible for breast tissue changes in male patients, but a thorough clinical assessment remains essential.

Gynaecomastia: Causes and Risk Factors

Gynaecomastia results from an oestrogen–androgen imbalance in breast tissue and has many causes, including hormonal changes, underlying conditions, recreational substances, and drug-induced effects from medicines such as spironolactone, antipsychotics, and some antidepressants.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity in breast tissue. It is a relatively common condition, with estimates suggesting it affects a substantial proportion of males at some point during their lifetime, with peaks occurring during the neonatal period, puberty, and older age (NICE Clinical Knowledge Summary: Gynaecomastia). It is important to distinguish true gynaecomastia — involving glandular tissue — from pseudogynaecomastia, which involves fatty tissue accumulation without glandular proliferation. In primary care, clinicians will typically take a thorough history (including duration, medication use, and substance use), perform a clinical examination, and assess relevant investigations to make this distinction.

The causes of gynaecomastia are wide-ranging and include:

• Hormonal changes: Elevated oestrogen, reduced testosterone, or raised prolactin levels

• Medications: A significant proportion of cases are drug-induced (see below)

• Underlying conditions: Liver disease, renal failure, hyperthyroidism, hypogonadism, and certain tumours

• Recreational substances: Cannabis, anabolic steroids, and alcohol are recognised contributors, though the evidence for some associations is based largely on case reports and observational data

• Idiopathic causes: In many cases, no clear cause is identified

Drug-induced gynaecomastia is a well-documented phenomenon. Medicines commonly implicated include spironolactone, cimetidine, some antipsychotics, opioids, and certain antidepressants — particularly those that raise prolactin by blocking dopamine receptors. SSRIs have been associated with gynaecomastia in rare cases, though the mechanism is not fully established and the evidence is largely limited to case reports. It is also worth noting that many patients presenting with gynaecomastia are taking multiple medicines simultaneously, making it challenging to attribute causality to any single agent. A thorough medication review — including over-the-counter medicines, herbal remedies, and supplements — is therefore an essential part of the clinical assessment (NICE CKS: Gynaecomastia; NHS: Gynaecomastia).

MHRA Guidance and Reported Side Effects of Bupropion

Gynaecomastia is not listed as a recognised adverse effect in the UK Zyban SmPC, and the MHRA has not established a regulatory link between bupropion and this condition; rare case reports exist but are frequently confounded.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for monitoring the safety of medicines and medical devices. The MHRA operates the Yellow Card scheme, which allows healthcare professionals and patients to report suspected adverse drug reactions (ADRs). Based on the current UK SmPC for Zyban (bupropion hydrochloride), available on the electronic Medicines Compendium (emc), gynaecomastia is not listed as a recognised adverse effect of bupropion.

The known and documented side effects of bupropion, as described in the Zyban SmPC, include:

• Very common or common: Dry mouth, insomnia, headache, nausea, dizziness, agitation, and tremor

• Less common: Tachycardia, hypertension, and sweating

• Serious but rare: Seizures, hypersensitivity reactions, and neuropsychiatric symptoms including mood changes

Importantly, the UK SmPC identifies several contraindications to bupropion use — not merely cautions. These include a current or prior history of seizure disorder, a current or prior diagnosis of an eating disorder (such as anorexia nervosa or bulimia nervosa), and abrupt withdrawal from alcohol or benzodiazepines. Prescribers should also be aware of bupropion's potential to lower the seizure threshold, particularly at higher doses or in patients with other predisposing factors such as head injury or concurrent use of medicines that affect seizure threshold. Clinicians and patients should refer to the full Zyban SmPC on the emc and the BNF for complete prescribing information.

With respect to gynaecomastia specifically, there is no established regulatory link between bupropion and this condition based on current MHRA or emc SmPC guidance. Whilst isolated case reports in the medical literature have occasionally noted breast-related changes in patients taking bupropion, these reports are rare and frequently confounded by other medicines or underlying conditions. Patients and clinicians should be cautious about attributing gynaecomastia solely to bupropion without a thorough clinical evaluation to exclude other causes.

When to Speak to a GP or Pharmacist

Men who notice breast enlargement, a hard or irregular lump, nipple discharge, or rapid breast changes whilst taking bupropion should seek prompt GP assessment; men aged 50 or over with a unilateral hard subareolar mass should be referred urgently via the 2-week-wait pathway.

Any male who notices breast tissue enlargement, tenderness, or a palpable lump beneath the nipple whilst taking bupropion — or any other medicine — should seek medical advice promptly. Whilst gynaecomastia is most often benign, it is important to rule out more serious underlying causes, including rare but significant conditions such as testicular tumours or male breast cancer, which can occasionally present with similar features (NHS: Gynaecomastia).

You should contact your GP if you experience:

• Unilateral breast swelling or a hard, irregular lump — this warrants prompt assessment to exclude malignancy

• Breast changes accompanied by nipple discharge

• Rapid or progressive breast enlargement

• Associated symptoms such as unexplained weight loss, fatigue, or testicular changes

In line with NICE guidance on suspected cancer recognition and referral (NICE NG12), men aged 50 or over with a unilateral, hard subareolar mass — with or without skin or nipple changes — should be referred urgently via the 2-week-wait pathway to exclude breast cancer. Suspicious features at any age also merit urgent referral. Your GP may arrange blood tests (which can include liver function tests, renal function, thyroid function, testosterone, LH, FSH, oestradiol, prolactin, and hCG) and examine the testes; imaging may be arranged if clinically indicated (NICE CKS: Gynaecomastia).

A pharmacist can also be a valuable first point of contact. They can review your full medication list — including over-the-counter medicines, herbal remedies, and supplements — to identify any agents more strongly associated with gynaecomastia, and advise on whether it is safe to continue your current medicine whilst awaiting a GP appointment.

If bupropion is suspected as a contributing factor, do not stop taking it abruptly without medical guidance. Abrupt discontinuation can lead to withdrawal symptoms or a relapse of the underlying condition being treated. Your GP or prescriber will be able to assess the risk–benefit balance and advise on whether a medication change is appropriate. Reporting suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) also helps build the national evidence base for drug safety monitoring.

Experiencing these side effects? Our pharmacists can help you navigate them →

Alternative Medicines and Shared Decision-Making

If bupropion is suspected to contribute to gynaecomastia, licensed alternatives for smoking cessation include varenicline and NRT; for depression (where bupropion would be off-label in the UK), NICE NG222 recommends SSRIs as first-line treatment via a shared decision-making approach.

If a clinical assessment suggests that a patient's medicine may be contributing to gynaecomastia, a discussion about alternative treatments is entirely appropriate. NICE guidance on depression in adults (NG222: Depression in adults: treatment and management) recommends a shared decision-making approach, taking into account the patient's preferences, previous treatment responses, comorbidities, and the side-effect profiles of available medicines. It should be noted that bupropion is not licensed for depression in the UK; if it has been prescribed off-label for this indication, the prescriber should review whether a licensed alternative is more appropriate.

For patients and clinicians considering licensed antidepressant options, the following points may be relevant:

• SSRIs (e.g., sertraline, fluoxetine, citalopram) are recommended as first-line treatment for depression and anxiety in the UK per NICE NG222. They have a low but non-zero association with gynaecomastia, based largely on case reports; the mechanism is not fully established.

• SNRIs (e.g., venlafaxine, duloxetine) similarly carry a low risk of prolactin-related side effects, though evidence on gynaecomastia risk is limited.

• Mirtazapine is associated with weight gain and sedation but does not typically cause significant prolactin elevation; evidence on gynaecomastia risk is limited.

• Tricyclic antidepressants (TCAs) are generally avoided as first-line treatment due to their broader side-effect and toxicity profile; some have been associated with hormonal effects, though the evidence base is largely observational.

For patients taking bupropion (Zyban) specifically for smoking cessation, licensed alternatives include varenicline and nicotine replacement therapy (NRT), which should be considered if bupropion is thought to be contributing to adverse effects.

Shared decision-making means that patients are active participants in choosing their treatment. Clinicians should explain the available evidence clearly, acknowledge areas of uncertainty — such as the limited and largely case-report-based data on bupropion and gynaecomastia — and respect patient concerns without dismissing them. If a patient is stable on their current medicine and the gynaecomastia is mild and non-progressive, it may be reasonable to continue treatment whilst monitoring the condition. Conversely, if breast changes are causing significant distress or are worsening, a supervised switch to an alternative agent may be the most appropriate course of action. Regular review and open communication between patient and prescriber remain central to safe, effective management (NICE NG222; BNF: antidepressant monographs).

Frequently Asked Questions